AKT1 and non-small cell lung carcinoma: Further investigations revealed that Sal B significantly down-regulated the expression of miR-23a and inhibited the PTEN/PI3K/AKT signaling pathway, suggesting its potential as a monotherapy or in combination therapy for NSCLC.